This article is more than 5 years old. Information may no longer be current.
Serum lactate dehydrogenase does not predict OS in myeloma
Click Here to Manage Email Alerts
NEW YORK — Serum lactate dehydrogenase at diagnosis provided no prognostic value with regard to OS among patients with multiple myeloma, according to study results presented at Lymphoma & Myeloma 2015.
Measurement of serum lactate dehydrogenase (LDH) release in combination with other approaches helps detect necrosis and damaged tissue. Serum LDH does provide prognostic significance in several hematologic malignancies, according to study background.
Dionisios Stoumbos, MD, of the department of hematology at Metaxa Memorial Cancer Hospital in Greece, and colleagues evaluated whether serum LDH provided prognostic value in relation to OS among an unselected group of untreated patients with multiple myeloma.
Researchers reviewed the records of all patients initially diagnosed with various stages of multiple myeloma at Metaxa Cancer Hospital between Jan. 1, 2000, and Dec. 31, 2007.
Stoumbos and colleagues analyzed serum LDH of 72 patients at diagnosis. The mean observation period was 88 months (standard deviation [SD], 43; median, 83). Fifty patients died during the observation period.
The investigators observed elevated serum LDH levels (> 300 U/L) in eight patients, and elevated levels correlated with serum concentrations of 2-microglobuline, hemoglobin and creatinine.
Researchers reported median survival of 90 months (SD, 42.3; mean, 87 months) among patients with serum LDH levels above 300 U/L and 88 months (SD, 43.8; mean, 87.8) among patients with lower serum LDH levels. – by Mark Leiser
Reference:
Stoumbos D, et al. Abstract P1. Presented at: Lymphoma & Myeloma 2015: An International Congress on Hematologic Malignancies; Oct. 22-24, 2015; New York.
Disclosure: The researchers report no relevant financial disclosures.